Login | Register

New Novartis Drug Shows Promise For Heart Failure



LCZ696, a first-in-class compound, may improve treatment outcomes for half of all patients with heart failure, according to a Phase II clinical trial on heart failure patients with preserved ejection fraction; preserved ejection fraction is when all the heart failure signs are present, but the heart’s left ventricle pumps out more blood when it contracts compared to others with heart failure…

Leave a Reply

Your email address will not be published. Required fields are marked *